Latest News by Industry
CHELMSFORD, Mass.--(BUSINESS WIRE)--Oct 31, 2022--
ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated Oxygen (SSO 2 ) Therapy has been awarded a group purchasing agreement for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier, Inc., effective as of July 1, 2022. The agreement allows Premier hospital members, at their discretion, to take advantage of special pricing and pre-negotiated terms to access SSO 2 Therapy for their ST-segment elevation (STEMI) heart attack patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005127/en/
ZOLL’s TherOx® SSO2 System delivers SSO2 therapy immediately post-PCI to reduce infarct size (Photo: Business Wire)
SSO 2 therapy is used immediately after stenting is performed for left-anterior descending (LAD) STEMI heart attacks – the most severe type – and within 6 hours of symptom onset. SSO 2 delivers high levels of dissolved oxygen directly to the heart to recover damaged tissue. Data have shown that SSO 2 is associated with lower rates of heart failure and death within one year. 1
“We are seeing increasing numbers of cardiologists realize the benefits of SSO 2 therapy to further reduce infarct size and improve outcomes for their heart attack patients,” said Christopher Barnabas, President of ZOLL Circulation. “Through this agreement, we are making this life-saving therapy more accessible via Premier’s vast network, with the shared goal of improving cardiovascular care.”
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 250,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.
About ZOLL
ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 46,000 employees around the world, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com.
Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.
___________
| 1 | Stone, G.W. et al. Circ Cardiovasc Interv; 2; 366-375. Sep 2009. |
Copyright © 2022 ZOLL Medical Corporation. All rights reserved. TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation and/or its subsidiaries in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners. |
View source version on businesswire.com:https://www.businesswire.com/news/home/20221031005127/en/
CONTACT: Media contact:
Matt Hogan
ZOLL
978-805-6561
media@zoll.com
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: TECHNOLOGY MEDICAL DEVICES HOSPITALS OTHER TECHNOLOGY CARDIOLOGY SOFTWARE OTHER HEALTH HEALTH GENERAL HEALTH
SOURCE: ZOLL
Copyright Business Wire 2022.
PUB: 10/31/2022 09:00 AM/DISC: 10/31/2022 09:01 AM
http://www.businesswire.com/news/home/20221031005127/en